Century Therapeutics, Inc. (IPSC) Stock Grade

About Century Therapeutics, Inc.'s fundamentals

Century Therapeutics is a small-cap biotechnology company with a market capitalization of $144.6 million that is not yet profitable, as evidenced by its negative net margin of -8.8% and net loss in its latest annual statement. The company has experienced explosive revenue growth of 1,556.8% year-over-year, suggesting rapidly expanding commercial activity or clinical development progress. As a pre-profitability biotech firm, the company does not pay dividends and traditional valuation metrics like P/E ratio and return on equity are not applicable. Investors should note that significant revenue growth in early-stage biotech companies does not guarantee future profitability, and the company remains in a capital-intensive development phase.